Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 0.45 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.45 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.39 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582671 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL1065994 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL5523617 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL30240916 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL23563168 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL8581971 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL23563167 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL9300366 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL14437195 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A | |
| SCHEMBL14268493 | 1.00 | ITPR3 (0.45) | ITPR3ITPR2ITPR1SMPD1INPP5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020102688-A1 | Nucleotide sequences coding polypeptide for use as anticoagulant and antiseptic | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2002-08-01 | — | — | US | disclosed |
| US-6268193-B1 | A NON-GLYCOSYLATED PROTEIN; THERAPEUTIC AGENT IN ORGAN TRANSPLANT REJECTION; THERAPEUTIC AGENT BLOCKING ATTACHMENT OF BACTERIAL, VIRAL, OR PARASITIC PATHOGENS GLYCOCONJUGATE RECEPTORS; CONTRACEPTIVE USES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2001-07-31 | — | — | US | disclosed |
| US-5955347-A | DNA FRAGMENT CODING FOR GLYCOSYLTRANSFERASES; USEFUL IN ISOLATION OF GLYCOSYLTRANSFERASES AND MODIFYING CELL SURFACE OLIGOSACCHARIDES STRUCTURES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1999-09-21 | — | — | US | disclosed |
| US-5770420-A | POLYPEPTIDE HAVING SPECIFIED AMINO ACID SEQUENCE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1998-06-23 | — | — | US | disclosed |
| US-5595900-A | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0654082-A4 | CLONING AND EXPRESSION OF A HUMAN -g(a)(1,3)FUCOSYLTRANSFERASE, FUCT-VI. | UNIV MICHIGAN (US) | 1997-01-02 | — | — | EP | disclosed |
| EP-0654082-A1 | CLONING AND EXPRESSION OF A HUMAN $g(a)(1,3)FUCOSYLTRANSFERASE, FUCT-VI | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1995-05-24 | — | — | EP | disclosed |
| US-5371203-A | Reacting a triester of L-fucose with trichloroacetonitrile to form corresponding trichloroacetimidate, followed by phosphating,hydrogenolysis, deprotecting, salt formation; a substrate for fucosyltransferases; tumor diagnosis | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-12-06 | — | — | US | disclosed |
| US-5324663-A | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-06-28 | — | — | US | disclosed |
| WO-1994002616-A1 | CLONING AND EXPRESSION OF A HUMAN α(1,3)FUCOSYLTRANSFERASE, FUCT-VI | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1994-02-03 | — | — | WO | disclosed |
| EP-0502298-A2 | Process for the stereo-selective preparation of beta-fucopyranosyl phosphates and very pure GDP-fucose | MERCK PATENT GmbH (DE) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020102688-A1 | Nucleotide sequences coding polypeptide for use as anticoagulant and antiseptic | RNGTT, NUDT21, CPSF1 | ITPR3 3081/4885ITPR2 3099/4885ITPR1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.